Albany, New York (09/26/2014) – According to reports, IGI Laboratories, Inc. (NYSEMKT:IG) has bought rights of 18 former products from AstraZeneca. IG is a well-known generic pharmaceutical company. As per the information, 17 out of 18 products that the company bought had been marketed. It has acquired all the patents, rights and related documents of these products.
Insights of the deal:
IGI Laboratories, Inc. (NYSEMKT:IG) has bought selling rights of 18 products, out of which 1 is suppository, and 17 are injectable products. Most of the products were marketed by the company; hence, they have the approval from U.S FDA. The current healthcare market in the United States of America is going through a flat phase, where there are a lot of opportunities for everyone. The individual success of a company or any person in this industry totally depends upon the technology used by that person or an organization. There are a lot of examples; that can tell the truth about the healthcare industry in US.
The one trend which has been followed closely over the past few years is the introduction of information technology. Those organizations that are using it well can post eye-steering figures while those that can’t make efficient use of it are the ones left behind. As per the IMS Health, the total valuation created by these 17 products that IGI Laboratories, Inc. (NYSEMKT:IG) has acquired was $200 million. The last updated date was recorded on May 2014.
Management of IGI Laboratories, Inc. (NYSEMKT:IG) is quite hopeful from the probable sales that these products will generate in coming months. If company can market these products well and place them in an ideal position, then it can surely get results up to expectations. Reporters tried to get in touch with someone from Astra Zeneca, but no one could be contacted. The company will soon start the fresh marketing campaigning for these products.